Europe Remote Patient Monitoring Devices Market Size & Share 2025 - 2034

Europe Remote Patient Monitoring Devices Market Size

The Europe remote patient monitoring devices market was estimated at USD 6.4 billion in 2024. The market is expected to grow from USD 7 billion in 2025 to USD 17.7 billion by 2034 at a CAGR of 10.9% during the forecast period, according to the latest report published by Global Market Insights Inc. The growth of this market is significantly driven by the rising incidence of chronic diseases, increasing disposable income and healthcare expenditure, technological advancement in remote patient monitoring devices, and growing aging population.

Leading players in the Europe remote patient monitoring devices market are Medtronic, Dexcom, Abbott Laboratories, Koninklijke Philips N.V., and Boston Scientific. These companies are expanding their product portfolios, integrating leading-edge technologies such as artificial intelligence (AI), internet of things (IoT), and cloud-based platforms and further developing their distribution networks to respond to the increased demand for cost-effective, accurate, simple-to-use remote patient monitoring systems throughout the Europe region. Their focus on creating quality solutions will allow for increased data sharing in real time and help create improved clinical outcomes while making it possible for patients to access preventative care and home-based care models more easily.
 

The market increased from USD 4.8 billion in 2021 to USD 5.9 billion in 2023. The rapid growth of elderly population in Europe is driving the demand for RPM devices. According to Eurostat, in January 2024, the population of the European Union was projected to be 449.3 million, with 21.6% over the age of 65. With an increasing number of older population, and an increased incidence of chronic illnesses such as cardiovascular disease, diabetes, respiratory disorders due to increased age, a need for continuous monitoring and timely intervention has developed. RPM devices enable providers to offer more efficient, at home care for older patients, thus decreasing the number of hospital admissions and increasing the quality of life of patients.
 

The growing prevalence of chronic diseases in Europe is a major driver for the adoption of remote patient monitoring devices. According to WHO Europe and the European Commission health reports, in 2024, chronic diseases accounted for 86% of all deaths in Europe and 77% of the total disease burden. Cardiovascular diseases alone caused 3.9 million deaths annually in Europe, while cancer is responsible for 22.3% of deaths in the EU, with approximately 3.7 million new cases reported annually across Europe. This escalating burden of chronic conditions necessitates continuous monitoring and early intervention, making RPM devices essential for improving patient outcomes, reducing hospital admissions, and supporting home-based care models. As healthcare systems shift toward preventive and value-based care, the demand for RPM solutions is expected to surge significantly across the region.
 

Furthermore, rising healthcare spending across Europe is a significant driver for the adoption of remote patient monitoring devices. According to Eurostat, healthcare expenditure in the EU reached EUR 1,720 billion in 2023, equivalent to 10.0% of gross domestic product (GDP). Among EU countries, Germany (11.7%), France (11.5%), Austria and Sweden (both 11.2%) recorded the highest healthcare expenditure relative to GDP in 2023. This sustained increase in healthcare investment reflects a growing commitment to advanced medical technologies and patient-centric care models.
 

As disposable incomes rise and governments allocate more resources to health systems, there is greater capacity to adopt innovative solutions like RPM devices, which help reduce hospital costs, improve chronic disease management, and support home-based care. Consequently, higher healthcare budgets and consumer spending power are accelerating the integration of remote monitoring technologies across Europe.
 

RPM devices are technologically advanced tools that allow for the continuous, real-time tracking of patient’s health apart from traditional clinical methods. These devices range from wearable sensors to implantable and handheld instruments, which monitor numerous physiological parameters such as heart rate, blood pressure, and blood glucose levels. By using RPM devices, data is transferred wirelessly to healthcare providers, allowing real-time health assessments, increasing patient engagement, and supporting value-based healthcare models.
 

Europe Remote Patient Monitoring Devices Market Trends

• The use of advanced technologies in remote patient monitoring (RPM) devices is currently revolutionizing healthcare delivery within Europe. With the incorporation of artificial intelligence (AI), innovations in wearable devices, improved sensor accuracy and telehealth connectivity, healthcare providers are able to provide better, more effective and tailored monitoring solutions to patients.
   
• Modern RPM devices increasingly incorporate Internet of Things (IoT) and AI, facilitating real-time data collection. Continuous monitoring allows clinicians to identify abnormal trends or sudden changes in vital signs immediately, enabling early intervention before conditions worsen. For instance, Welch Allyn Connex 360 Vital Signs Monitor by Baxter International captures vital signs (BP, SpO2, temperature, respiration) in few minutes and sends data securely to EMRs via DeviceBridge cloud platform for real-time access.
   
• Additionally, breakthroughs in biosensor technology have improved the accuracy and reliability of monitoring devices. Contemporary sensors can track diverse physiological metrics, including blood oxygen levels, respiratory rates, and sleep patterns. A notable example is BioIntelliSense’s BioButton, a wearable solution offering continuous monitoring through advanced biosensors and a centralized BioDashboard system. These technological innovations are significantly driving the growth of the RPM market by enhancing precision, convenience, and patient engagement.
   

Europe Remote Patient Monitoring Devices Market Analysis

Based on product, the Europe remote patient monitoring devices market is divided into cardiac monitoring devices, blood pressure monitoring devices, neurological monitoring devices, respiratory monitoring devices, multiparameter monitoring devices, blood glucose monitoring devices, fetal and neonatal monitoring devices, sleep monitoring devices, and other products. The blood glucose monitoring devices segment held revenues of USD 3.5 billion in the year 2024 and the segment is poised for significant growth at a CAGR of 11.1% during the forecast period.
 

• Technological progress in blood glucose monitoring devices has greatly increased the use of remote patient monitoring (RPM) solutions in Europe. Continuous glucose monitoring (CGM) systems and smart glucometers connected to telehealth platforms allow real-time tracking and data sharing, which improves diabetes management and patient outcomes.  Innovations like AI integration and improved sensor technology have boosted the accuracy and reliability of glucose monitoring devices. AI analytics provide predictions about glucose trends, helping clinicians and patients make better choices regarding diet, medication, and lifestyle changes.
   
• For example, Dexcom’s G7 Continuous Glucose Monitoring system provides real-time glucose readings every five minutes. It works with mobile apps and telehealth platforms to send data to healthcare providers smoothly. Similarly, Abbott’s FreeStyle Libre system lets patients scan sensors for immediate glucose readings and share data remotely with clinicians, enabling proactive care.
   
• Glucose monitors allow consistent, non-intrusive monitoring of blood sugar. With this technology, the risk of developing serious complications like diabetic ketoacidosis is significantly reduced, promoting the use of these devices.
   
• By providing useful insights and alerts, blood glucose monitoring devices help patients manage their condition effectively while lowering hospital visits and healthcare costs. Together, these elements contribute to strong growth in the blood glucose monitoring sector within Europe’s RPM market.
   

Based on application, the Europe remote patient monitoring devices market is bifurcated into cardiovascular diseases, cancer, diabetes, neurological disorders, infectious diseases respiratory diseases, and other applications. The diabetes segment dominated the market with 55.4% market share in 2024.
 

• The rising prevalence of diabetes is a major driver for the adoption of remote patient monitoring (RPM) devices in Europe. According to the International Diabetes Federation (IDF, 2024), an estimated 66 million adults (aged 20–79 years) in Europe are living with diabetes, representing about 1 in 10 adults. Alarmingly, 33.6% of these cases remain undiagnosed, highlighting the urgent need for continuous monitoring solutions. This trend underscores the growing demand for advanced monitoring technologies to manage the disease effectively.
   
• Diabetes management requires frequent tracking of blood glucose levels, HbA1c, and insulin administration, which traditional methods often fail to address efficiently. RPM devices bridge this gap by offering continuous, real-time monitoring, enabling better glycemic control and personalized care.
   
• RPM devices can provide early identification of problematic complications such as hypoglycemia and hyperglycemia by offering a means for patients to engage actively with their health care provider, making timely diagnoses easier for the physician while decreasing the likelihood of critical events. Therefore, RPM solutions are a key force driving advancement within the diabetes space and generating rapid growth while enhancing patient involvement with clinical decision-making.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the Europe remote patient monitoring devices market is bifurcated into home-care settings, long-term care, and other end users. The home-care settings segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 11.1%.
 

• The increasing preference for home-based healthcare is driving the adoption of remote patient monitoring (RPM) devices in Europe. Patients with chronic conditions such as cardiovascular diseases, diabetes, and respiratory disorders are seeking convenient and effective solutions that allow them to manage their health outside of traditional clinical settings.
   
• Advanced RPM devices enable continuous tracking of vital signs and provide real-time alerts, making home care safer and more efficient. These systems empower patients to monitor their health proactively, reducing the need for frequent hospital visits and improving overall quality of life.
   
• Technological innovations have made RPM devices more accurate, user-friendly, and comfortable to wear. Many devices now integrate seamlessly with smartphones and digital health apps, allowing patients to easily track their data and share it with healthcare providers for timely interventions.
   
• By offering convenience, safety, and improved health outcomes, RPM devices are becoming a cornerstone of home care, significantly contributing to market growth.

The Germany remote patient monitoring devices market was valued at USD 1 billion and USD 1.1 billion in 2021 and 2022, respectively. The market size reached USD 1.3 billion in 2024, growing from USD 1.2 billion in 2023.
 

• The growing burden of cardiovascular diseases in Germany is a key factor accelerating the adoption of remote patient monitoring (RPM) devices. According to the World Heart Observatory, Germany recorded 319,026 deaths due to cardiovascular diseases (CVD) in 2021. This high mortality rate underscores the need for continuous cardiac monitoring to detect arrhythmias and other heart-related complications early. RPM devices equipped with real-time tracking and alert systems enable timely interventions, reduce hospitalizations, and support home-based care, making them essential for managing cardiovascular health in Germany.
   
• Similarly, diabetes prevalence is driving RPM adoption in the country. As per the International Diabetes Federation (IDF) Diabetes, an estimated 6.5 million adults (aged 20–79 years) in Germany were living with diabetes in 2024. Effective diabetes management requires continuous monitoring of blood glucose levels and early detection of complications such as hypoglycemia and hyperglycemia. RPM devices provide real-time glucose tracking and seamless data sharing with healthcare providers, improving treatment adherence and patient outcomes. These trends highlight that rising incidence of chronic diseases is fueling the growth of Germany’s RPM devices market.
   

UK remote patient monitoring devices market accounted for USD 939.7 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The increasing proportion of aging population in the UK is a key factor boosting the adoption of remote patient monitoring (RPM) devices. According to the Office for National Statistics (ONS), in 2022, there were around 12.7 million people aged 65 or over in the UK, representing 19% of the population, and this share is projected to rise to 27% by 2072. This demographic shift is associated with a higher prevalence of chronic conditions such as cardiovascular diseases, diabetes, and respiratory disorders, which require continuous monitoring and timely intervention.
   
• RPM devices enable real-time tracking of vital signs, early detection of health deterioration, and improved home-based care, reducing hospital visits and healthcare costs. As the aging population continues to grow, the demand for RPM solutions in the UK is expected to surge significantly.
   

France remote patient monitoring devices market is anticipated to witness considerable growth over the analysis period.
 

• The growing prevalence of chronic diseases in France is a major factor accelerating the adoption of remote patient monitoring (RPM) devices. Cardiovascular diseases remain the leading cause of mortality, with 152,728 deaths recorded in 2021 according to World Heart Observatory. Similarly, diabetes is a significant health concern, as more than 3.8 million people in France were treated with medication for diabetes in 2023, representing 5.6% of the population. These conditions require continuous monitoring and timely intervention to prevent complications.
   
• RPM devices provide real-time tracking of vital signs such as heart rate and blood glucose levels, enabling early detection of abnormalities and reducing hospital visits. As chronic disease rates continue to rise, the demand for RPM solutions in France is expected to grow substantially, supporting home-based care and improving patient outcomes.
   

Italy remote patient monitoring devices market is anticipated to grow at the CAGR of 10.4% during the analysis timeframe.
 

• Rising healthcare expenditure in Italy is a key factor supporting the growth of remote patient monitoring (RPM) devices. According to Eurostat Healthcare Expenditure Statistics 2025, Italy spent EUR 179 billion on healthcare in 2023, making it one of the highest spenders in the EU after Germany and France. This substantial investment reflects the country’s commitment to improving healthcare infrastructure and adopting advanced technologies.
   
• Higher healthcare budgets enable hospitals, clinics, and home care providers to integrate RPM solutions for chronic disease management, real-time monitoring, and preventive care. As disposable incomes also rise, patients are increasingly willing to adopt innovative, connected health devices for convenience and better outcomes. These factors collectively drive strong demand for RPM devices in Italy, positioning the market for significant growth in the coming years.
   

Spain remote patient monitoring devices market is predicted to grow significantly over the forecast period.
 

• Spain’s remote patient monitoring devices market is witnessing strong growth driven by rapid technological advancements and the increasing adoption of digital health solutions. Innovations such as AI-powered analytics, IoT-enabled devices, and wearable sensors are transforming chronic disease management and home-based care.
   
• Additionally, Spain faces significant demographic and health challenges that amplify the need for RPM solutions. According to WHO, 22.3% of Spain’s population was aged 65 years and over in 2023, reflecting a rapidly aging society. Coupled with a high prevalence of chronic conditions such as hypertension, diabetes, and cardiovascular diseases, the demand for continuous monitoring and early intervention is surging. These factors collectively position Spain as a key growth market for RPM technologies in Europe.
   

Netherlands remote patient monitoring devices market is poised to witness substantial growth during the forecast period.
 

• Government initiatives promoting e-health and strong infrastructure for telehealth have accelerated RPM deployment, particularly for managing chronic conditions and supporting home-based care. These advancements are improving efficiency, reducing costs, and enhancing patient satisfaction.
   
• Demographic trends and chronic disease prevalence further strengthen the case for RPM adoption in the Netherlands. The country’s aging population is growing steadily, and projections indicate a sharp rise in age-related health issues. According to RIVM, 10.5 million Dutch residents had at least one chronic disease in 2022, a figure expected to reach nearly 12 million by 2050, driven largely by conditions such as dementia and osteoarthritis. This surge in chronic illnesses, combined with an older population requiring continuous care, underscores the importance of RPM devices for early detection, remote management, and improved health outcomes.
   

Europe Remote Patient Monitoring Devices Market Share

• The top 5 players of the market account for approximately 77% of the market share which includes companies such as Medtronic, Dexcom, Abbott Laboratories, Koninklijke Philips N.V., and Boston Scientific.
   
• These companies maintain their dominance in the market through innovative product launches, extensive distribution networks and strong regulatory approval. Moreover, strategic partnerships with research institutes and government agencies play a primary role in advancing the development of advanced remote patient monitoring devices and getting the necessary permits.
   
• Additionally, the integration of artificial intelligence (AI) and machine learning into remote patient monitoring systems is revolutionizing the way healthcare providers analyze patient data. These technologies enable predictive analytics, early detection of complications, and personalized treatment plans, which significantly improve patient outcomes. Companies investing in AI-driven RPM solutions are likely to gain a competitive edge as healthcare systems across Europe increasingly prioritize data-driven decision-making and proactive care models.
   
• Furthermore, the growing adoption of cloud-based platforms and interoperability standards is enhancing the scalability and efficiency of remote monitoring solutions. By ensuring seamless data exchange between devices, electronic health records (EHRs), and telehealth platforms, manufacturers are addressing one of the major challenges in RPM deployment like data fragmentation further helping market to grow.
   

Europe Remote Patient Monitoring Devices Market Companies

Some of the eminent market participants operating in the Europe remote patient monitoring devices industry include:
 

• Abbott Laboratories
• Baxter International
• BIOTRONIK
• Boston Scientific
• Dexcom
• F. Hoffmann-La Roche
• GE Healthcare
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic
• OMRON
• Sotera Wireless
• Vital Connect
  
   
• Boston Scientific

Boston Scientific has a strong product portfolio, leading to larger adoption and significant market expansion. Boston specializes in implantable cardiac monitoring solutions, such as LATITUDE, a remote patient monitoring system.
 

• Koninklijke Philips N.V.

Koninklijke Philips invests in research & development, fostering innovation and growth. The company continuously evolves with the newest advancement in RPM devices.
 

• Medtronic

Medtronic has strong geographical presence, which enables it to enhance its market reach. Medtronic operates in most of the countries in Europe, thus comprising a robust distribution network.
 

Europe Remote Patient Monitoring Devices Industry News:

• In July 2025, OMRON Healthcare and Tricog Health launched KeeboHealth, an AI-powered remote cardiac care platform integrating OMRON’s connected devices with Tricog’s real-time analytics to detect early signs of heart deterioration, which helped the company advance its ‘Going for Zero’ vision, improve cardiac outcomes, and scale remote monitoring across India’s healthcare system.
   
• In April 2024, Philips partnered with smartQare to integrate its viQtor solution with Philips clinical monitoring platforms, enabling continuous patient monitoring in and out of hospitals across Europe, and as part of the agreement, smartQare acquired Philips Healthdot business to combine wearable biosensors with remote monitoring on a unified platform, which helped Philips streamline its remote care offerings, reduce clinical workload, and expand its presence in the European remote patient monitoring market.
   

The Europe remote patient monitoring devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Cardiac monitoring devices
• Blood pressure monitoring devices
• Neurological monitoring devices
• Respiratory monitoring devices
• Multiparameter monitoring devices
• Blood glucose monitoring devices
• Fetal and neonatal monitoring devices
• Sleep monitoring devices
• Other products

Market, By Application

• Cardiovascular diseases
• Cancer
• Diabetes
• Neurological disorders
• Infectious diseases
• Respiratory diseases
• Other applications

Market, By End Use

• Home-care settings
• Long-term care
• Other end use

The above information is provided for the following countries:

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Poland
• Switzerland
• Netherlands